Study of Inetetamab with Pyrotinib and Vinorelbine
for Treating HER2-Positive Advanced Breast Cancer
Led by Zhejiang Cancer Hospital · Updated on 2023-05-12
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining inetetamab with pyrotinib and vinorelbine for treating HER2-positive advanced breast cancer in a real-world setting. This prospective, observational study involves a single group of participants and aims to gather information through patient consent, case collection, and ongoing observation and follow-up. The study is sponsored by Zhejiang Cancer Hospital and focuses on a specific patient population with advanced disease.
Participants will receive the combination treatment of inetetamab, pyrotinib, and vinorelbine during the treatment period. The study includes several periods screening, treatment, and survival and follow-up phases. There are no comparison groups or interventions beyond this single treatment approach, and the study does not involve randomization or placebo controls.
During participation, individuals will undergo evaluations including tumor progression monitoring and adverse event assessments for up to 48 months. Researchers will measure outcomes such as progression-free survival, overall survival, objective response rate, and disease control rate. The study involves collecting clinical data and following up regularly to assess treatment effects and safety over time.
CONDITIONS
Brief Title
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
Research Team
C
Chen zhanhong
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed HER2-positive advanced breast cancer by cytology or histology
HER2 positive defined as >10% immunoreactive cells with IHC score 3 or HER2 gene amplification by ISH
Advanced breast cancer defined as locally advanced or metastatic cancer not suitable for surgery
Adequate organ function to tolerate chemotherapy and anti-HER2 treatments, with LVEF and QT intervals within safe range
ECOG performance status score of 0 to 2
Voluntary signing of informed consent form
Use of contraception during the study and for 6 months after treatment, and not lactating
You will not qualify if you...
Pregnant or breastfeeding women
History of other metastatic or potentially metastatic malignant tumors within 5 years, except certain cured cancers
Known allergy to any study drug components
History of immunodeficiency including HIV positive or other acquired/congenital immunodeficiency
Any condition the researcher judges as unsuitable for study participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to about 48 months or until disease progression or discontinuation
Participants receive inetetamab combined with pyrotinib and vinorelbine for advanced breast cancer.
Visits occur as part of routine care with assessments for treatment response and safety
Survival and Follow-up
Duration - Up to about 48 months
Participants are monitored for overall survival and long-term safety after treatment ends.
Follow-up visits according to clinical practice for survival assessment
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Study of Inetetamab with Pyrotinib and Vinorelbine
for Treating HER2-Positive Advanced Breast Cancer
Phase 1a1b Open-Label Study Assessing BBO-10203 Alone and with Other Cancer Drugs in Advanced Solid Tumors
Phase 3 Study Comparing TQB2930 Plus Chemotherapy to Trastuzumab Plus Chemotherapy
in Adults With HER2-Positive Advanced Breast Cancer Who Have Had Prior Anti-HER2 Treatments
Randomized Study of Trastuzumab Rezetecan With or Without Radiotherapy in HER2-positive Advanced Breast Cancer With Brain Metastases
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.